Norbert G.  Riedel net worth and biography

Norbert Riedel Biography and Net Worth

CEO of Aptinyx
Dr. Riedel is executive chairman and former chief executive officer of Aptinyx. He was formerly president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals, Cerevel Therapeutics, Eton Pharmaceuticals, and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired in February 2017. Dr. Riedel is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council. He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine and, prior to moving into industry, was an associate professor of medicine at Boston University School of Medicine and a visiting professor at the Massachusetts Institute of Technology. Dr. Riedel received a Diploma and Ph.D. from the University of Frankfurt and was a postdoctoral fellow at Harvard University.

What is Norbert G. Riedel's net worth?

The estimated net worth of Norbert G. Riedel is at least $34,803.74 as of January 10th, 2020. Dr. Riedel owns 362,539 shares of Aptinyx stock worth more than $34,804 as of November 21st. This net worth evaluation does not reflect any other investments that Dr. Riedel may own. Learn More about Norbert G. Riedel's net worth.

How do I contact Norbert G. Riedel?

The corporate mailing address for Dr. Riedel and other Aptinyx executives is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. Aptinyx can also be reached via phone at (847) 871-0377 and via email at [email protected]. Learn More on Norbert G. Riedel's contact information.

Has Norbert G. Riedel been buying or selling shares of Aptinyx?

Norbert G. Riedel has not been actively trading shares of Aptinyx in the last ninety days. Most recently, on Monday, December 6th, Norbert G. Riedel bought 100,000 shares of Aptinyx stock. The stock was acquired at an average cost of $2.23 per share, with a total value of $223,000.00. Learn More on Norbert G. Riedel's trading history.

Who are Aptinyx's active insiders?

Aptinyx's insider roster includes Robert Hombach (Director), Ashish Khanna (CFO), Joan Miller (Director), and Norbert Riedel (CEO). Learn More on Aptinyx's active insiders.

Norbert G. Riedel Insider Trading History at Aptinyx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2021Buy100,000$2.23$223,000.00View SEC Filing Icon  
1/10/2020Buy35,000$3.00$105,000.00362,539View SEC Filing Icon  
6/25/2018Buy2,400$16.00$38,400.00View SEC Filing Icon  
See Full Table

Norbert G. Riedel Buying and Selling Activity at Aptinyx

This chart shows Norbert G Riedel's buying and selling at Aptinyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptinyx Company Overview

Aptinyx logo
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Read More

Today's Range

Now: $0.10
Low: $0.09
High: $0.10

50 Day Range

MA: $0.08
Low: $0.06
High: $0.10

2 Week Range

Now: $0.10
Low: $0.01
High: $0.72

Volume

231,100 shs

Average Volume

1,317,051 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27